Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of safety and efficacy of biphasic human insulin IU 100 to EX1000 on glycaemic control in subjects with type 2 diabetes

Trial Profile

Assessment of safety and efficacy of biphasic human insulin IU 100 to EX1000 on glycaemic control in subjects with type 2 diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs EX 1000; Insulin suspension isophane/insulin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Sep 2012 Planned number of patients changed from 400 to 480.
    • 25 Aug 2011 New source identified and integrated (Clinical Trial Registry - India, CTRI2008-091-000035).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top